Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Cepheid Gets FDA Approval for Trichomonas Test in Men

Cepheid Gets FDA Approval for Trichomonas Test in Men

Sep 07, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Cepheid said yesterday that the US Food and Drug Administration has expanded its approval for Xpert TV, the company's urine-based test for trichomonas, to include its use in symptomatic and asymptomatic men.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  2. DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

  3. Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

  4. Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

  5. Bio-Techne, Qiagen Expand Partnership on Exosome Technology

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.